Author:
Shin Yong-Won,Moon Jangsup,Cho Yong Won,Kim Dong Wook,Hong Sang Bin,Kim Do-Yong,Chang Hyeyeon,Yoon Seo Hyun,Yu Kyung-Sang,Jang In-Jin,Lee Soon-Tae,Jung Keun-Hwa,Park Kyung-Il,Jung Ki-Young,Kim Manho,Chu Kon,Lee SeungHwan,Lee Sang Kun
Subject
Behavioral Neuroscience,Neurology (clinical),Neurology
Reference11 articles.
1. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels;Errington;Mol Pharmacol,2008
2. Tolerability, pharmacokinetics, and bioequivalence of the tablet and syrup formulations of lacosamide in plasma, saliva, and urine: saliva as a surrogate of pharmacokinetics in the central compartment;Cawello;Epilepsia,2013
3. Comparison of lacosamide concentrations in cerebrospinal fluid and serum in patients with epilepsy;May;Epilepsia,2015
4. Acute or chronic use of lacosamide does not alter its distribution between serum and cerebrospinal fluid;Michelhaugh;Epilepsia,2015
5. U.S. Food and Drug Administration. Vimpat ® (lacosamide): highlights of prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022255s026s027,022254s019s020,022255s012s013lbl.pdf. Accessed July 30, 2020.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献